Pfizer obtains commercial rights and interests of cresemba in Europe

Source: Sina Pharmaceutical Co., Ltd June 14, 2017, Pfizer and Basilea, a Swiss anti infective and anti-tumor drug R & D enterprise, said that they had reached a license agreement on the exclusive commercial rights and interests of cresemba (isavuconazole), which was used by Pfizer for the treatment of invasive aspergillosis and mucormycosis in Europe The incidence rate of invasive aspergillosis and Mucor mycosis is high, and the incidence rate of immune aspergillosis is also high According to the license agreement, Pfizer has obtained exclusive sales rights in Europe (including Australia, France, Italy, Germany and the United Kingdom), and the regions without sales rights are Nordic countries, including Denmark, Finland, Iceland, Sweden and Norway In addition, Pfizer needs to be responsible for other listing operations of cresemba in 2017 and 2018, mainly in Europe Basilea will retain cresemba's EU marketing license holder qualification Richard Blackburn, global president of Pfizer (Europe, Africa and the Middle East) and bioequivalent drugs, said: "the inclusion of cresemba in our huge antifungal assets once again demonstrates our commitment to providing innovative treatments for patients with fungal infections We believe that through the company's global layout in the antifungal market and the reserve of professional knowledge in the field of antifungal, we will be able to meet the current clinical needs that are still not satisfied " "Cresemba is an innovative and effective drug for the treatment of invasive fungal infections, as demonstrated by its market performance in the United States and some European countries," said Ronald Scott, chief executive of Basilea pharmaceuticals Pfizer has a long-term successful record in the sales of antifungal drugs Through this cooperation, we will maximize the clinical value of cresemba in Europe " Since its pioneering achievements in penicillin development in the 1940s, Pfizer has been adhering to the research and development of innovative anti infection drugs, as well as the educational work of patients and clinicians In December 2016, Pfizer completed the acquisition of AstraZeneca's small molecule anti infection business unit, including drugs already on sale and drugs in clinical development outside the United States.